J. Peter van Tintelen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Peter van Tintelen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Maarten P. van Den Berg
Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen
3 shared publications - Gerard Pals
Department of Human Genetics, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
2 shared publications J. J. J. Aalberts
Department of Cardiology, Thorax Centre, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
2 shared publicationsKarin Y. van Spaendonck-Zwarts
Department of Genetics, University Medical Center Groningen, University of Groningen , Groningen
2 shared publicationsA. A. M. Wilde
Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
1 shared publicationA. G. Schuurman
1 shared publication
Latest Publications
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 12 (6) , 532-534
Lamin A/C-Related Cardiac Disease and Pregnancy
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 12 (6) , 532-534
Lamin A/C-Related Cardiac Disease and Pregnancy
- 1 February 2010
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 18 (2) , 85-89
Recurrent and founder mutations in the Netherlands
Background/Methods. Marfan syndrome (MFS) is a heritable connective tissue disorder usually caused by a mutation in the fibrillin 1 (FBN1) gene. Typical characteristics of MFS that have been described include dolichostenomelia, ectopia lentis and aortic root dilatation. However, there is great clinical variability in the expression of the syndrome’s manifestations, both between and within families. Here we discuss the clinical variability of MFS by describing a large fourgeneration Dutch family with MFS. Results. Nineteen individuals of one family with a single missense FBN1 mutation (c.7916A>G) were identified. The same mutation was found in one unrelated person. Clinical variability was extensive and not all mutation carriers fulfilled the diagnostic criteria for MFS. Some patients only expressed mild skeletal abnormalities, whereas aortic root dilation was present in eight patients, an acute type A aortic dissection was recorded in two other patients, and a mitral valve prolapse was present in eight patients. In some patients cardiac features were not present on initial screening, but did however develop over time. Conclusion. MFS is a clinically highly variable syndrome, which means a meticulous evaluation of suspected cases is crucial. Mutation carriers should be re-evaluated regularly as cardiovascular symptoms may develop over time. (Neth Heart J 2010;18:85–9.)
- 1 February 2010
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 18 (2) , 85-89
Recurrent and founder mutations in the Netherlands
Background/Methods. Marfan syndrome (MFS) is a heritable connective tissue disorder usually caused by a mutation in the fibrillin 1 (FBN1) gene. Typical characteristics of MFS that have been described include dolichostenomelia, ectopia lentis and aortic root dilatation. However, there is great clinical variability in the expression of the syndrome’s manifestations, both between and within families. Here we discuss the clinical variability of MFS by describing a large fourgeneration Dutch family with MFS. Results. Nineteen individuals of one family with a single missense FBN1 mutation (c.7916A>G) were identified. The same mutation was found in one unrelated person. Clinical variability was extensive and not all mutation carriers fulfilled the diagnostic criteria for MFS. Some patients only expressed mild skeletal abnormalities, whereas aortic root dilation was present in eight patients, an acute type A aortic dissection was recorded in two other patients, and a mitral valve prolapse was present in eight patients. In some patients cardiac features were not present on initial screening, but did however develop over time. Conclusion. MFS is a clinically highly variable syndrome, which means a meticulous evaluation of suspected cases is crucial. Mutation carriers should be re-evaluated regularly as cardiovascular symptoms may develop over time. (Neth Heart J 2010;18:85–9.)
- 1 November 2009
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 17 (11) , 407-408
Recurrent and founder mutations in inherited cardiac diseases in the Netherlands
- 1 November 2009
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 17 (11) , 407-408
Recurrent and founder mutations in inherited cardiac diseases in the Netherlands
- 1 November 2009
- Published by Elsevier in Heart Rhythm
- Vol. 6 (11) , 1574-1583
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene
- 1 November 2009
- Published by Elsevier in Heart Rhythm
- Vol. 6 (11) , 1574-1583
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene
- 1 September 2008
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 16 (9) , 299-304
The many faces of aggressive aortic pathology: Loeys-Dietz syndrome
Background: Loeys-Dietz syndrome (LDS) is a newly recognised disorder of connective tissue which shares overlapping features with Marfan syndrome (MFS) and the vascular type of Ehlers- Danlos syndrome, including aortic root dilatation and skin abnormalities. It is clinically classified into types 1 and 2. LDS type 1 can be recognised by craniofacial characteristics, e.g. hypertelorism, bifid uvula or cleft palate, whereas these are absent in LDS type 2. It is important to recognise LDS because its vascular pathology is aggressive. We describe nine LDS patients from four families, relate their features to published cases, and discuss important aspects of the diagnosis and management of LDS in order to make clinicians aware of this new syndrome. Results: Characteristics found in the majority of these LDS patients were aortic root dilatation, cleft palate and/or a bifid/abnormal uvula. Conclusion: Because aortic dissection and rupture in LDS tend to occur at a young age or at aortic root diameters not considered at risk in MFS, and because the vascular pathology can be seen throughout the entire arterial tree, patients should be carefully followed up and aggressive surgical treatment is mandatory. Clinicians must therefore be aware of LDS as a cause of aggressive aortic pathology and that its distinguishing features can sometimes be easily recognised. (Neth Heart J 2008;16:299-304.)
- 1 September 2008
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 16 (9) , 299-304
The many faces of aggressive aortic pathology: Loeys-Dietz syndrome
Background: Loeys-Dietz syndrome (LDS) is a newly recognised disorder of connective tissue which shares overlapping features with Marfan syndrome (MFS) and the vascular type of Ehlers- Danlos syndrome, including aortic root dilatation and skin abnormalities. It is clinically classified into types 1 and 2. LDS type 1 can be recognised by craniofacial characteristics, e.g. hypertelorism, bifid uvula or cleft palate, whereas these are absent in LDS type 2. It is important to recognise LDS because its vascular pathology is aggressive. We describe nine LDS patients from four families, relate their features to published cases, and discuss important aspects of the diagnosis and management of LDS in order to make clinicians aware of this new syndrome. Results: Characteristics found in the majority of these LDS patients were aortic root dilatation, cleft palate and/or a bifid/abnormal uvula. Conclusion: Because aortic dissection and rupture in LDS tend to occur at a young age or at aortic root diameters not considered at risk in MFS, and because the vascular pathology can be seen throughout the entire arterial tree, patients should be carefully followed up and aggressive surgical treatment is mandatory. Clinicians must therefore be aware of LDS as a cause of aggressive aortic pathology and that its distinguishing features can sometimes be easily recognised. (Neth Heart J 2008;16:299-304.)